U.S. Electrical Stock News

Masco (NYSE:MAS) announced the upcoming retirements of its Group President of Plumbing and Wellness and its Vice President of the Masco Operating System. The company is reorganizing its leadership so that the heads of its four largest businesses report directly to the CEO. New appointments are being made in supply chain and procurement to reinforce these functions as part of the executive reshuffle. For investors watching Masco at a share price of $71.24, this leadership transition comes...

Arcosa (ACA) has released its Q1 2026 numbers, with revenue of US$571.7 million and basic EPS of US$0.48, setting the tone for investors focused on how earnings and margins are holding up into the new fiscal year. Over the past few quarters, the company has seen revenue move from US$632.0 million in Q1 2025 to a peak of US$797.8 million in Q3 2025 before landing at US$571.7 million in the latest period. Basic EPS has ranged from US$0.48 in Q1 2025 to US$1.49 in Q3 2025 and now sits at US$0.48...

If you are wondering whether MPLX is still reasonably priced at around US$56.61, the key question is how its current market value compares with its fundamentals. The unit price sits at US$56.61 after a 2.3% move over the last week, 1.2% over the past month, 5.1% year to date and 18.1% over the past year. A 3 year return of 109.0% and a 5 year return of 205.7% provide useful context for long term holders. Recent coverage has focused on MPLX's role in US energy infrastructure and its position...

If you are asking whether BlackRock at around US$1,061.68 is priced high, low, or somewhere in between, the answer depends on how you look at its valuation. The stock has returned 1.6% over the last 7 days, 10.9% over the last 30 days, and 16.6% over the last year, while the year to date return sits at a 2.2% decline and the 3-year and 5-year returns are 76.8% and 36.9% respectively. Recent price moves sit against a backdrop of ongoing attention on BlackRock's role as a major global asset...

In the first quarter of 2026, SiteOne Landscape Supply reported essentially flat sales of US$940.1 million and a net loss of US$26.6 million, while delivering 14% adjusted EBITDA growth through gross margin gains and tighter cost control. The company also closed its acquisition of Reinders, a Midwest irrigation and agronomics distributor, which management believes offers meaningful synergy potential and supports its acquisition-led expansion. With that context, we’ll now examine how margin...

Proto Labs (PRLB) opened 2026 with Q1 results that follow a year in which trailing 12 month revenue came in at about US$533.1 million and basic EPS reached US$0.89, alongside a 28% gain in earnings and a net profit margin of 4% versus 3.3% the year before. Over recent quarters, the company has seen quarterly revenue move from US$121.8 million in Q4 2024 to US$126.2 million in Q1 2025 and then to US$136.5 million in Q4 2025. Basic EPS shifted from a small loss of US$0.02 in Q4 2024 to US$0.15,...

Wabash National (WNC) has just put fresh numbers on the table, with recent quarters showing revenue between about US$321 million and US$459 million and EPS ranging from a loss of US$1.23 to a gain of US$5.41. Trailing twelve month figures for Q4 2025 show US$1.54 billion in revenue and EPS of US$5.09. Over the past six reported quarters, revenue has moved from US$2.13 billion on a trailing basis in Q3 2024 to US$1.54 billion by Q4 2025, and EPS has shifted from a trailing loss of US$5.17 to a...

If you are looking at Janus Henderson Group and wondering whether the recent share price really reflects what the company is worth, this breakdown is designed to help you frame that question clearly. The stock last closed at US$51.60, with returns of 0.1% over 7 days, 0.4% over 30 days, 8.0% year to date, 49.2% over 1 year, 121.0% over 3 years and 71.9% over 5 years. These figures raise fair questions about how much of this is already priced in and how risk is being viewed. Recent coverage...

Kailera Therapeutics, NasdaqGS:KLRA, completed its initial public offering and began trading as a public company. The company implemented a restated certificate of incorporation and amended bylaws that adjust board structure, shareholder rights, and forum selection. Kailera Therapeutics was added to the NASDAQ Composite Index, increasing its visibility among index-tracking investors. With NasdaqGS:KLRA now trading at $25.15, Kailera Therapeutics has moved into the public markets with fresh...

Monte Rosa Therapeutics recently presented preclinical data at the AACR 2026 meeting in San Diego showing its first-in-class cyclin E1-directed molecular glue degrader, MRT-55811, produced selective cyclin E1 degradation, downstream pathway suppression, and tumor regression in CCNE1-amplified models. The work suggests a potential way to directly target a historically “undruggable” oncogene across multiple CCNE1-amplified solid tumors while sparing non-amplified cells. We’ll now look at how...

American Financial Group (AFG) opened 2026 earnings season with Q1 results that follow a solid 2025 finish, where Q4 revenue was US$2.0b, basic EPS came in at US$3.58, and net income excluding extra items was US$299m. Over recent quarters the company has seen revenue range from US$1.8b to US$2.3b, while quarterly basic EPS moved from US$1.84 in Q1 2025 to US$3.58 in Q4 2025. This gives a clear view of how profits have tracked alongside a trailing 12 month net margin of 10.6% compared with...

Cellebrite recently appointed Shiven Ramji, formerly of Okta/Auth0, as President of Products and Technology, succeeding Ronnen Armon following a transition period, and it is preparing to report its March 2026-quarter results on 14 May with consensus expectations for higher earnings and revenue than the prior year. Ramji’s track record leading a very large annual recurring revenue business and focus on AI adoption across Cellebrite’s platform may influence how investors assess the company’s...

If you are wondering whether Northwest Natural Holding is fairly priced, expensive, or a potential value idea right now, this article walks through what the current numbers indicate. The stock last closed at US$52.86, with returns of 13.1% year to date and 27.7% over the past year, so recent performance may be prompting fresh questions about risk and reward. Recent news coverage has largely focused on how regulated utilities like Northwest Natural Holding fit into portfolios that may be...

Ermenegildo Zegna (ZGN) shares reacted after the group reported Q1 2026 revenue growth of 2.5% year on year, with 7.4% organic growth supported by Direct to Consumer sales and stronger results in the Americas. See our latest analysis for Ermenegildo Zegna. The Q1 2026 update comes on the back of strong recent momentum, with a 30 day share price return of 14.55% and a 90 day share price return of 43.15%. The 1 year total shareholder return of 59.13% points to gains that go beyond short term...

If you are wondering whether On Holding's current share price reflects its true value, this breakdown will help you line up the story the numbers are telling. The stock recently closed at US$34.54, with returns of 4.7% decline over the past week, 0.7% decline over the past month, and 26.4% decline year to date, while the 1-year return sits at 29.4% decline and the 3-year return at 1.9%. Recent coverage has focused on how the stock's pullback contrasts with its longer term performance,...

CF Industries Holdings, Inc. recently declared a US$0.50 per-share quarterly dividend on its common stock, payable on May 29, 2026, to shareholders of record as of May 15, 2026, alongside shareholder approval of all director nominees, say-on-pay, and auditor ratification. Management highlighted strong 2025 operating achievements, including 10.10 million tons of ammonia production, record low safety incidents, US$1.70 billion returned to shareholders, and progress on low-carbon ammonia and...

Melco Resorts & Entertainment (NasdaqGS:MLCO) heads into its Q1 2026 update with recent quarterly numbers that put revenue at about US$1.3b in Q4 2025 and basic EPS at US$0.16. This caps off a year where trailing twelve month EPS reached US$0.46 on revenue of roughly US$5.2b. Over the past few quarters, the company has seen revenue range between US$1.2b and US$1.3b per quarter, while basic EPS moved from US$0.08 in Q1 2025 to US$0.19 in Q3 before landing at US$0.16 in Q4. This result comes...

Ares Management (NYSE:ARES) has appointed Peter Ogilvie as Chief Operating Officer and Head of Strategy. Ogilvie is tasked with driving global growth initiatives across the firm’s platform. The move reflects a leadership shift that could influence how Ares pursues expansion and integration of future acquisitions. Ares Management, trading at $119.0, has mixed recent performance, with a 3.3% return over the past week and 12.5% over the past month, set against a 28.5% decline year to date and...

Q2 Holdings (NYSE:QTWO) has introduced new AI driven fraud prevention tools focused on continuous account takeover protection. The company has also rolled out Q2 Treasury Fulfillment, a solution aimed at streamlining and automating treasury onboarding for commercial clients. Both features expand Q2's digital banking platform beyond its recent earnings updates, targeting fraud risk and onboarding friction for financial institutions. Q2 Holdings enters this product update cycle with its...

Caterpillar has caught the eye of many investors lately, and if you are wondering whether the current share price offers good value, the numbers provide a useful starting point. At a last close of US$889.67, the stock has delivered returns of 7.1% over 7 days, 21.8% over 30 days, 48.7% year to date, 177.8% over 1 year, 332.8% over 3 years and 303.7% over 5 years. That naturally raises questions about how much of the story is already reflected in the price. Recent headlines around Caterpillar...

In late April 2026, Merck reported stronger-than-expected first-quarter results, raised its full-year revenue and earnings guidance, and secured FDA approval for IDVYNSO, a complete two-drug HIV-1 regimen for virologically suppressed adults. Together with advancing oncology programs such as KEYTRUDA-based regimens and WELIREG in renal cell carcinoma, these developments reinforce Merck’s efforts to broaden growth drivers ahead of expected pressure on legacy products. We’ll now examine how...

Xenon Pharmaceuticals (XENE) is back in focus after presenting Phase 3 X-TOLE2 data for azetukalner in adults with focal onset seizures, supported by long term X-TOLE extension and real world no titration feedback. See our latest analysis for Xenon Pharmaceuticals. The latest clinical update has arrived after a strong few quarters for the stock, with a 36.87% 90 day share price return and a 46.63% 1 year total shareholder return that suggest momentum has been building around Xenon’s lead...

Arteris (AIP) shares were in focus after the company announced a new collaboration with MIPS, a GlobalFoundries company, to support physical AI computing platforms across automotive, robotics, and embedded computing markets. See our latest analysis for Arteris. The collaboration news arrives after a strong run in Arteris shares, with a 30 day share price return of 64.96% and a year to date share price return of 85.82%. The 1 year total shareholder return is 330.80% and the 3 year total...

GoDaddy (GDDY) opened 2026 with Q1 revenue of US$1.27 billion and basic EPS of US$1.61, setting the tone for how its hosting and domains business is translating scale into earnings. The company reported quarterly revenue of US$1.19 billion in Q1 2025 and US$1.27 billion in Q1 2026, with basic EPS moving from US$1.55 to US$1.61 over the same period, while trailing twelve month EPS reached US$6.39 on US$5.02 billion of revenue. With net profit margin at 17.3% over the last year, these results...